Ponsegromab vs Visugromab

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: GDF-15 · full Non-Small Cell Lung Cancer pipeline

Ponsegromab

Developed by Pfizer

Phase 2 in Non-Small Cell Lung Cancermonoclonal antibody
Weak signal

NCT04299048 · Phase 1 · completed

Every participant in this small study received the same drug with no placebo or control group, so the reported adverse-event and laboratory-abnormality rates cannot be attributed to the drug versus the underlying advanced cancer and cachexia; all patients had an adverse event and roughly 40% had a serious adverse event, including one death.

Next expected readout: May 2028 · NCT07663630 (registry estimate)

Reported efficacy

Body weight change at week 12: Weight change at week 12: +2.02 kg (100mg), +3.00 kg (200mg), +5.37 kg (400mg) vs placebo -0.41 kg (all p<0.001) (met)

Result source: NCT05546476

Visugromab

Developed by CatalYm GmbH

Phase 2 in Non-Small Cell Lung Cancermonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: March 2029 · NCT07098988 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointPonsegromabVisugromab
PFS, median—Not reported—Not reported
OS, median—Not reported—Not reported
ORR—Not reported—Not reported
Duration of response, median—Not reported—Not reported

PFS, median

Ponsegromab
—Not reported
Visugromab
—Not reported

OS, median

Ponsegromab
—Not reported
Visugromab
—Not reported

ORR

Ponsegromab
—Not reported
Visugromab
—Not reported

Duration of response, median

Ponsegromab
—Not reported
Visugromab
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Visugromab: no structured comparison results are available for Non-Small Cell Lung Cancer.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Ponsegromab: 3 of 4 rows · Visugromab: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricPonsegromab
Dropout rate
36.4%a
NCT04299048 · Phase 1 · monotherapy
show 2 more results
—200mg Q3W
NCT04803305 · Phase 1 · registry result, not featured evidence
25%200mg Q3W
NCT04803305 · Phase 1 · registry result, not featured evidence
Discontinued due to AEs
—a
NCT04299048 · Phase 1 · monotherapy
show 2 more results
—200mg Q3W
NCT04803305 · Phase 1 · registry result, not featured evidence
—200mg Q3W
NCT04803305 · Phase 1 · registry result, not featured evidence
Serious AEs
40%a
NCT04299048 · Phase 1 · monotherapy
show 2 more results
25%200mg Q3W
NCT04803305 · Phase 1 · registry result, not featured evidence
41.7%200mg Q3W
NCT04803305 · Phase 1 · registry result, not featured evidence
Most frequent reported AEs
a
anaemia 50%
diarrhoea 50%
fatigue 40%
NCT04299048 · Phase 1 · monotherapy
show 2 more results
200mg Q3W
urinary tract infection 25% (placebo 16.7%)
anaemia 8.3% (placebo 0%)
hypercalcaemia 8.3% (placebo 0%)
NCT04803305 · Phase 1 · registry result, not featured evidence
200mg Q3W
urinary tract infection 25% (placebo 16.7%)
lethargy 16.7% (placebo 0%)
nausea 16.7% (placebo 0%)
NCT04803305 · Phase 1 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Ponsegromab

Cachexia Appetite 1.84 vs 2.45 placebo score @ 4wk200mg Q3W
absolute change · score
NCT04803305 · Phase 1 · registry result, not featured evidence
show 5 more results
2.19 vs 0.99 placebo score @ 1wk200mg Q3W
NCT04803305 · Phase 1 · registry result, not featured evidence
2.21 vs 1.11 placebo score @ 2wk200mg Q3W
NCT04803305 · Phase 1 · registry result, not featured evidence
2.3 vs 1.27 placebo score @ 3wk200mg Q3W
NCT04803305 · Phase 1 · registry result, not featured evidence
1.95 vs 1.95 placebo score @ 5wk200mg Q3W
NCT04803305 · Phase 1 · registry result, not featured evidence
1.61 vs 2.41 placebo score @ 6wk200mg Q3W
NCT04803305 · Phase 1 · registry result, not featured evidence
Cachexia Fatigue 1.52 vs 1.84 placebo score @ 1wk200mg Q3W
absolute change · score
NCT04803305 · Phase 1 · registry result, not featured evidence
show 5 more results
-2.12 vs 0.04 placebo score @ 2wk200mg Q3W
NCT04803305 · Phase 1 · registry result, not featured evidence
-0.49 vs -1.21 placebo score @ 3wk200mg Q3W
NCT04803305 · Phase 1 · registry result, not featured evidence
-0.55 vs -1 placebo score @ 4wk200mg Q3W
NCT04803305 · Phase 1 · registry result, not featured evidence
-0.24 vs -0.92 placebo score @ 5wk200mg Q3W
NCT04803305 · Phase 1 · registry result, not featured evidence
0.74 vs -1.13 placebo score @ 6wk200mg Q3W
NCT04803305 · Phase 1 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ponsegromab's landscape · Visugromab's landscape